|Bid||0.0000 x 1000|
|Ask||0.0000 x 2200|
|Day's Range||1.7400 - 1.7700|
|52 Week Range||1.0200 - 1.9100|
|Beta (5Y Monthly)||0.92|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
If you want to know who really controls Savara Inc. ( NASDAQ:SVRA ), then you'll have to look at the makeup of its...
AUSTIN, Texas, July 11, 2022--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of three abstracts for poster presentation at the ERS International Congress 2022 to be held in-person and virtually, September 4-6, 2022 in Barcelona, Spain.
Savara, The LGL Group, and Harte Hanks are part of zacks Screen of the Week article.